AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31054015 — intervention group
Group type: EXPERIMENTAL
Intervention: transcranial random noise stimulation (tRNS)
Number of subjects: 17
Study 30128656 — intervention group
Group type: EXPERIMENTAL
Intervention: CRNNFA with EEMF spectral profiles of Catechol, Hydroquinone, Indole, and Tryptophan mixtures
Number of subjects: 0
Study 30128656 — intervention group
Group type: EXPERIMENTAL
Intervention: CRNNFA with TSFS spectral profiles of Benzo[a] Pyrene, Chrysene, and Pyrene mixtures
Number of subjects: 0
Study 30128656 — intervention group
Group type: EXPERIMENTAL
Intervention: CRNNFA with both EEMF and TSFS data sets
Number of subjects: 0
Study 25759942 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Training (ACT)
Number of subjects: 113
Study 25759942 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (reflection seminars)
Number of subjects: 113
Study 24937510 — intervention group
Group type: EXPERIMENTAL
Intervention: Student team visitation
Number of subjects: 330
Study 24937510 — intervention group
Group type: COMPARATOR
Intervention: Limited intervention (control group)
Number of subjects: 330
Study 22759866 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg levobupivacaine (group L)
Number of subjects: 80
Study 22759866 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg tramadol (group T)
Number of subjects: 80
Study 22759866 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg tramadol plus 100 mg levobupivacaine (group LT)
Number of subjects: 80
Study 22759866 — intervention group
Group type: COMPARATOR
Intervention: Saline (group C)
Number of subjects: 80
Study 20499203 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback retraining (BFB)
Number of subjects: 60
Study 20499203 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injection
Number of subjects: 60
Study 20499203 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial division of puborectalis (PDPR)
Number of subjects: 60
Study 17620671 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1955
Study 17620671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1955
Study 17620671 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TVR vs no TVR)
Number of subjects: 1955
Study 15598194 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary medical care (≥ 2 visits)
Number of subjects: 391
Study 11505416 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAUMEEL S (mouth rinse, 5 times daily for a minimum of 14 days)
Number of subjects: 32
Study 11505416 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mouth rinse, 5 times daily for a minimum of 14 days)
Number of subjects: 32
Study 9052357 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and ticlopidine pretreatment
Number of subjects: 68
Study 9052357 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (Control)
Number of subjects: 68
Study 7966526 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women
Number of subjects: 259
Study 7966526 — intervention group
Group type: COMPARATOR
Intervention: Newborns (cord blood)
Number of subjects: 259
Study 7966526 — intervention group
Group type: COMPARATOR
Intervention: Newborns
Number of subjects: 259
Study 7966526 — intervention group
Group type: COMPARATOR
Intervention: Post-partum women
Number of subjects: 259
Study 3670227 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (100 MRC U)
Number of subjects: 0
Study 3670227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31373922 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan and amlodipine
Number of subjects: 142
Study 31373922 — intervention group
Group type: COMPARATOR
Intervention: Losartan and hydrochlorothiazide
Number of subjects: 142
Study 31373922 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 142
Study 28727491 — intervention group
Group type: EXPERIMENTAL
Intervention: POC Xpert MTB/RIF test performed at a primary health care clinic
Number of subjects: 1297
Study 28727491 — intervention group
Group type: COMPARATOR
Intervention: Xpert MTB/RIF test performed at a district hospital laboratory
Number of subjects: 1297
Study 24433306 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 24
Study 24433306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23984604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients after recent ACS (group I)
Number of subjects: 86
Study 23984604 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (group II)
Number of subjects: 86
Study 23984604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients after ACS
Number of subjects: 86
Study 23984604 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 86
Study 21948782 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 34
Study 21948782 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Training (WT)
Number of subjects: 34
Study 19781416 — intervention group
Group type: EXPERIMENTAL
Intervention: Early abciximab administration (EA) in high-risk patients (n = 413)
Number of subjects: 1650
Study 19781416 — intervention group
Group type: COMPARATOR
Intervention: Late abciximab administration (LA) in high-risk patients (n = 203)
Number of subjects: 1650
Study 19781416 — intervention group
Group type: EXPERIMENTAL
Intervention: Early abciximab administration (EA) in low-risk patients (n = 314)
Number of subjects: 1650
Study 19781416 — intervention group
Group type: COMPARATOR
Intervention: Late abciximab administration (LA) in low-risk patients (n = 156)
Number of subjects: 1650
Study 16407020 — intervention group
Group type: COMPARATOR
Intervention: Liquid supper
Number of subjects: 200
Study 16407020 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna
Number of subjects: 200
Study 16407020 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate solution
Number of subjects: 200
Study 16407020 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐ELS
Number of subjects: 200
Study 15584844 — intervention group
Group type: EXPERIMENTAL
Intervention: False positive normative feedback, no opportunity to reaffirm self-concept
Number of subjects: 160
Study 15584844 — intervention group
Group type: EXPERIMENTAL
Intervention: False negative normative feedback, no opportunity to reaffirm self-concept
Number of subjects: 160
Study 15584844 — intervention group
Group type: EXPERIMENTAL
Intervention: False positive normative feedback, opportunity to reaffirm self-concept
Number of subjects: 160
Study 15584844 — intervention group
Group type: EXPERIMENTAL
Intervention: False negative normative feedback, opportunity to reaffirm self-concept
Number of subjects: 160
Study 11237929 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1 g EPA plus DHA daily, containing 720 mg EPA + 280 mg DHA)
Number of subjects: 0
Study 11237929 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil (80:20 mix of palm and sunflower seed oils)
Number of subjects: 0
Study 11237929 — intervention group
Group type: COMPARATOR
Intervention: ALA (2 g daily)
Number of subjects: 0
Study 11237929 — intervention group
Group type: COMPARATOR
Intervention: GLA (770 mg daily)
Number of subjects: 0
Study 11237929 — intervention group
Group type: COMPARATOR
Intervention: AA (680 mg daily)
Number of subjects: 0
Study 11237929 — intervention group
Group type: COMPARATOR
Intervention: DHA (720 mg daily)
Number of subjects: 0
Study 8986685 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal administration of 100 micrograms/d E2
Number of subjects: 20
Study 8986685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8362228 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin treatment for 7 days
Number of subjects: 40
Study 8362228 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin treatment
Number of subjects: 40
Study 8362228 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 40
Study 8362228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no M. catarrhalis)
Number of subjects: 40
Study 3496948 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (120 mg/d) by constant intravenous infusion
Number of subjects: 24
Study 3496948 — intervention group
Group type: COMPARATOR
Intervention: Isotonic dextrose solution
Number of subjects: 24
Study 30508890 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (90 kVp/395 mAs, contrast agent dosage of 1.2 mL/kg)
Number of subjects: 118
Study 30508890 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (120 kVp/200 mAs, contrast agent dosage of 1.5 mL/kg)
Number of subjects: 118
Study 30508890 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (90 kVp)
Number of subjects: 118
Study 30508890 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Protocols
Number of subjects: 118
Study 27077342 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Women on the Road to Health (WORTH)
Number of subjects: 306
Study 27077342 — intervention group
Group type: COMPARATOR
Intervention: Traditional WORTH
Number of subjects: 306
Study 27077342 — intervention group
Group type: COMPARATOR
Intervention: Wellness Promotion control group
Number of subjects: 306
Study 25190051 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG stimulation in patients with SCD
Number of subjects: 15
Study 25190051 — intervention group
Group type: COMPARATOR
Intervention: Control group (relatives and normal individuals)
Number of subjects: 15
Study 23357439 — intervention group
Group type: EXPERIMENTAL
Intervention: FFT-High Risk version (FFT-HR; 12 sessions of psychoeducation and training in communication and problem-solving skills)
Number of subjects: 40
Study 23357439 — intervention group
Group type: COMPARATOR
Intervention: Education control (EC; 1-2 family sessions)
Number of subjects: 40
Study 21357965 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Ponseti method (plaster change three times per week)
Number of subjects: 40
Study 21357965 — intervention group
Group type: COMPARATOR
Intervention: Standard Ponseti method (plaster change weekly)
Number of subjects: 40
Study 18070980 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin, 1,000 mg daily
Number of subjects: 29
Study 18070980 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin, 400 mg daily
Number of subjects: 29
Study 18070980 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin, 400 mg daily
Number of subjects: 29
Study 16826112 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of the subchondral bone plate
Number of subjects: 50
Study 16826112 — intervention group
Group type: COMPARATOR
Intervention: Retention of the subchondral bone plate
Number of subjects: 50
Study 16826112 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 14679153 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF chemotherapy (n = 360)
Number of subjects: 1063
Study 14679153 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF followed by goserelin (n = 357)
Number of subjects: 1063
Study 14679153 — intervention group
Group type: COMPARATOR
Intervention: Goserelin alone (n = 346)
Number of subjects: 1063
Study 14679153 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (CMF -> goserelin)
Number of subjects: 1063
Study 14679153 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (for ER-positive patients)
Number of subjects: 1063
Study 14679153 — intervention group
Group type: COMPARATOR
Intervention: Goserelin alone (for ER-positive patients)
Number of subjects: 1063
Study 11127233 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated nets (ITNs) with permethrin, 0.5 g/m2
Number of subjects: 3666
Study 11127233 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated chaddars with permethrin, 1 g/m2
Number of subjects: 3666
Study 11127233 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual spraying of houses with lambdacyhalothrin, 30 mg/m2
Number of subjects: 3666
Study 11127233 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3666
Study 8617578 — intervention group
Group type: EXPERIMENTAL
Intervention: 6S-LV
Number of subjects: 50
Study 8617578 — intervention group
Group type: COMPARATOR
Intervention: 6R,S-LV
Number of subjects: 50
Study 8617578 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU with 6S-LV
Number of subjects: 50
Study 2678876 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg
Number of subjects: 60
Study 2678876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 949903 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasone butyrate cream or ointment
Number of subjects: 100
Study 949903 — intervention group
Group type: COMPARATOR
Intervention: 0.0125% flurandrenolone cream or ointment
Number of subjects: 100
Study 949903 — intervention group
Group type: EXPERIMENTAL
Intervention: clobetasone butyrate
Number of subjects: 100
Study 30824364 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained inmate peer educators providing health education and active case finding in intervention prisons (n=8)
Number of subjects: 18032
Study 30824364 — intervention group
Group type: COMPARATOR
Intervention: Existing passive case finding system in control prisons (n=8)
Number of subjects: 18032
Study 27790789 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg and sofosbuvir 400 mg daily for 8 weeks (Group A1, n=20)
Number of subjects: 63
Study 27790789 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg and sofosbuvir 400 mg daily for 12 weeks (Group A2, n=20)
Number of subjects: 63
Study 27790789 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg and sofosbuvir 400 mg daily for 12 weeks (Group B, n=23)
Number of subjects: 63
Study 25985992 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass Testing and Treatment Intervention (MTAT) using rapid diagnostic tests (RDTs) and artemether-lumefantrine (AL)
Number of subjects: 0
Study 25985992 — intervention group
Group type: COMPARATOR
Intervention: No Mass Testing and Treatment Intervention (Standard of Care)
Number of subjects: 0
Study 24836471 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography monitoring combined with standard respiratory monitoring
Number of subjects: 427
Study 24836471 — intervention group
Group type: COMPARATOR
Intervention: Standard respiratory monitoring (standard care)
Number of subjects: 427
Study 22594858 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermotherapy (single session at 50°C)
Number of subjects: 273
Study 22594858 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimoniate (20 mg Sb5/kg weight/day for 20 days)
Number of subjects: 273
Study 19281114 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive resin cement (RelyX Unicem)
Number of subjects: 30
Study 19281114 — intervention group
Group type: COMPARATOR
Intervention: Multistep adhesive (Syntac) with Variolink II low viscosity (Control)
Number of subjects: 30
Study 17223022 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioadhesive formulations (LM-5, LM-12, chitosan G210) delivered using a nasal drop device
Number of subjects: 0
Study 17223022 — intervention group
Group type: COMPARATOR
Intervention: Non-bioadhesive control delivered with the same nasal drop device
Number of subjects: 0
Study 17223022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin formulation administered with a nasal spray system
Number of subjects: 0
Study 17223022 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioadhesive formulations
Number of subjects: 0
Study 15156901 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication treatment
Number of subjects: 736
Study 15156901 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic therapy
Number of subjects: 736
Study 15156901 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 736
Study 15156901 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment visual analogical score
Number of subjects: 736
Study 15156901 — intervention group
Group type: EXPERIMENTAL
Intervention: Control visits
Number of subjects: 736
Study 15156901 — intervention group
Group type: EXPERIMENTAL
Intervention: Health resources used
Number of subjects: 736
Study 12401244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (2 g bolus over 15 min, followed by 17 g infusion over 24 h)
Number of subjects: 6213
Study 12401244 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching)
Number of subjects: 6213
Study 12401244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 6213
Study 9649951 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + Glipizide (I + G)
Number of subjects: 37
Study 9649951 — intervention group
Group type: COMPARATOR
Intervention: Insulin + Placebo (I + P)
Number of subjects: 37
Study 7484520 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 78
Study 7484520 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium combined with Imipramine
Number of subjects: 78
Study 1962618 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg bid
Number of subjects: 466
Study 1962618 — intervention group
Group type: COMPARATOR
Intervention: Nizatidine 300 mg hs
Number of subjects: 466
Study 7236871 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 5 mg
Number of subjects: 17
Study 7236871 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 10 mg
Number of subjects: 17
Study 7236871 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 17
Study 7236871 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 20-640 mg d-1
Number of subjects: 17
Study 7236871 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (various doses)
Number of subjects: 17
Study 30903276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative indocyanine green (ICG) angiography
Number of subjects: 240
Study 30903276 — intervention group
Group type: COMPARATOR
Intervention: Subjective visual evaluation of bowel perfusion without ICG (Control)
Number of subjects: 240
Study 31235458 — intervention group
Group type: EXPERIMENTAL
Intervention: Orsiro sirolimus-eluting stent (BP-SES)
Number of subjects: 575
Study 31235458 — intervention group
Group type: COMPARATOR
Intervention: XIENCE Prime/Xpedition everolimus-eluting stent (PP-EES)
Number of subjects: 575
Study 29121979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (TIC) for 4 weeks
Number of subjects: 110
Study 29121979 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor plus Aspirin (TIC + ASP) for 4 weeks
Number of subjects: 110
Study 29121979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (TIC)
Number of subjects: 110
Study 29121979 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor plus Aspirin (TIC + ASP)
Number of subjects: 110
Study 26194769 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser surgery
Number of subjects: 0
Study 26194769 — intervention group
Group type: COMPARATOR
Intervention: Scalpel surgery
Number of subjects: 0
Study 23085863 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadofosveset (0.03 mmol/kg)
Number of subjects: 35
Study 23085863 — intervention group
Group type: COMPARATOR
Intervention: Gadobutrol (0.1 mmol/kg)
Number of subjects: 35
Study 21251179 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2189265 (LY) 0.1 to 12 mg, single escalating subcutaneous injections
Number of subjects: 6
Study 21251179 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2189265 (LY) doses ≥1.0 mg
Number of subjects: 6
Study 21251179 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2189265 (LY) doses ≥3.0 mg
Number of subjects: 6
Study 21251179 — intervention group
Group type: COMPARATOR
Intervention: LY2189265 (LY) during OGTT
Number of subjects: 6
Study 19729238 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 103
Study 19729238 — intervention group
Group type: COMPARATOR
Intervention: Suture
Number of subjects: 103
Study 17593957 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 10 mg/kg, given once daily for 7 days
Number of subjects: 390
Study 17593957 — intervention group
Group type: COMPARATOR
Intervention: Cefixime 20 mg/kg/day given in two divided doses for 7 days
Number of subjects: 390
Study 15034229 — intervention group
Group type: EXPERIMENTAL
Intervention: Climodien 2/3 (estradiol valerate 2 mg + dienogest 3 mg)
Number of subjects: 48
Study 15034229 — intervention group
Group type: COMPARATOR
Intervention: Estradiol valerate 2 mg
Number of subjects: 48
Study 15034229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11511790 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of 20% human albumin followed by 160 mg of furosemide
Number of subjects: 7
Study 11511790 — intervention group
Group type: COMPARATOR
Intervention: Sham solution followed by 160 mg of furosemide
Number of subjects: 7
Study 10990129 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference measurement
Number of subjects: 0
Study 10990129 — intervention group
Group type: COMPARATOR
Intervention: Waist:hip ratio
Number of subjects: 0
Study 7516361 — intervention group
Group type: EXPERIMENTAL
Intervention: Total paracentesis with dextran‐40 infusion (8 g per liter of ascitic fluid removed)
Number of subjects: 80
Study 7516361 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 80
Study 7516361 — intervention group
Group type: EXPERIMENTAL
Intervention: Total paracentesis with dextran‐40 infusion
Number of subjects: 80
Study 2660563 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times per day)
Number of subjects: 83
Study 2660563 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice per day)
Number of subjects: 83
Study 2660563 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 83
Study 2660563 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 83
Study 30691746 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill aerobic exercises (30 min, three sessions per week for six weeks)
Number of subjects: 20
Study 30691746 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual daily activities)
Number of subjects: 20
Study 29174216 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP XR-OS under fasted conditions
Number of subjects: 30
Study 29174216 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP XR-OS under fed conditions
Number of subjects: 30